Clinical trials: Cardiovascular Condition
Atrial Fibrillation, Atrial Flutter
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation.
- Trial name
- NCT01976507
- Testing
- dabigatran etexilate mesylate
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Vanderbilt University Medical Center
Acute Ischemic Stroke
Caffeinol Hypothermia Protocol
Caffeinol is a combination of caffeine and alcohol. The amount given is about the same as 1-2 glasses of wine and 3-4 cups of coffee. The patient receives a one time dose given over two hour while being cooled to 34.5 C.
- Trial name
- NCT00299416
- Testing
- Caffeinol, hypothermia
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
High Blood Pressure
Breathe: Slow Paced Breathing to Lower Blood Pressure
The purpose of this study is to investigate the nature of the physiological reasons for the decreases in resting blood pressure that can result from systematic practice of computer-guided breathing exercises or meditative…
- Trial name
- NCT00328016
- Testing
- Guided Breathing, RESPeRATE
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
Essential Hypertension
Helius in Hypertension-I: The UK Hypertension Registry
The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.
- Trial name
- NCT02553512
- Testing
- Ingestible Sensor and Wearable Sensor
- Volunteers
- 151 people
- Sponsor
- Proteus Digital Health, Inc.
Carotid Artery Stenosis, Strokes
Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes
The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA…
- Trial name
- STANCE (NCT02850081)
- Testing
- Statin, Atorvastatin
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Columbia University
Cardiovascular Disease, Diabetes Mellitus, Type 2
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.
- Trial name
- REWIND (NCT01394952)
- Testing
- Dulaglutide
- Where
- 300 sites in United States, Argentina and 23 more
- Volunteers
- 9,901 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Giant Cell Arteritis
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis…
- Trial name
- NCT02531633
- Testing
- Sirukumab, Prednisone
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Endothelial Dysfunction
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
We will study the hypothesis that long-term Tekturna treatment will improve endothelial function and the production and function of endothelial progenitor cells (EPCs) in patients with early atherosclerosis.
- Trial name
- NCT01067326
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Systemic Lupus Erythematosus
Efficacy of Fish Oil in Lupus Patients
The investigators hypothesize that low-dose dietary supplementation with omega-3 fish oil will improve disease activity and endothelial function in Systemic Lupus Erythematosus (SLE) patients.
- Trial name
- NCT00828178
- Testing
- Omega-3, flow-mediated dilation of the brachial artery, corn starch
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Michelle Petri M.D.,MPH
Peripheral Arterial Disease
Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)
This is a multi-center, non-randomized, single arm study of the SilverHawk™ /TurboHawk™ plaque excision systems when used in conjunction with SpiderFX™ embolic protection device in treatment of moderate to severely calcified…
- Trial name
- NCT00733135
- Testing
- SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device
- Volunteers
- 133 people
- Sponsor
- Medtronic Endovascular
Congenital Heart Disease
Pharmacokinetics of Acetaminophen in Pediatric Patients With Congenital Heart Disease
This is a prospective study of pediatric patients with congenital heart disease, in which acetaminophen serum concentrations will be measured following a single intraoperative intravenous dose of acetaminophen.
- Trial name
- NCT04278625
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter Winch
Pulmonary Hypertension
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models.
- Trial name
- NCT02587325
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Stroke, Hemiparesis
Error Enhancement of the Velocity Component
The purpose of this pilot study was to explore the impact of enhancement of the velocity component error in the course of reaching movements of the impaired/hemiparetic limb in an acute stroke subject.
- Trial name
- NCT02017093
- Testing
- Error Enhancement, control treatment
- Where
- Israel
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Haifa
Patent Ductus Arteriosus
Timing of PDA Closure and Respiratory Outcome in Premature Infants
The investigators propose the present study with the following aims: to determine whether early patent ductus arteriosus (PDA) treatment with ibuprofen treatment at the onset of clinical symptoms is superior to late ibuprofen…
- Trial name
- NCT00802685
- Testing
- Early ibuprofen
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Miami
Primary Disease
Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be observed in this study is intracardiac thrombus.
- Trial name
- DAWA (NCT01868243)
- Testing
- Dabigatran, Warfarin
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Hospital Ana Nery
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Breast Cancer, Coronary Artery Disease
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.
- Conditions
- Breast Cancer, Coronary Artery Disease, Stroke, Type2 Diabetes
- Trial name
- NCT04717050
- Testing
- Progressive combine training (PCT), Attention Control (AC)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Dana-Farber Cancer Institute
Coronary Arteriosclerosis, Acute Coronary Syndromes
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a…
- Trial name
- NCT00097591
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 13,619 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.